Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone240-268-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$34.29 million
Profitability
Miscellaneous
Employees373
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Novavax (NASDAQ:NVAX) Frequently Asked Questions
What is Novavax's stock symbol?
Novavax trades on the NASDAQ under the ticker symbol "NVAX."
When did Novavax's stock split? How did Novavax's stock split work?
Shares of Novavax reverse split on the morning of Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.
How were Novavax's earnings last quarter?
Novavax, Inc. (NASDAQ:NVAX) released its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts' consensus estimates of ($1.61) by $0.08. The biopharmaceutical company earned $3.36 million during the quarter, compared to analyst estimates of $3.53 million. During the same quarter in the previous year, the company posted ($2.40) earnings per share. View Novavax's Earnings History.
When is Novavax's next earnings date?
What price target have analysts set for NVAX?
9 equities research analysts have issued 12 month target prices for Novavax's stock. Their forecasts range from $7.00 to $90.00. On average, they expect Novavax's share price to reach $43.00 in the next year. This suggests a possible upside of 468.0% from the stock's current price. View Analyst Price Targets for Novavax.
What is the consensus analysts' recommendation for Novavax?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novavax.
What are Wall Street analysts saying about Novavax stock?
Here are some recent quotes from research analysts about Novavax stock:
- 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (9/4/2019)
- 2. HC Wainwright analysts commented, "We derived our price target of $12 using DCF methodology with a 30% discount rate, 2% terminal growth rate, and a clinical program probability-of-success of 72%. Risks to our investment thesis include failure of clinical trials, regulatory requirements for additional clinical studies, unproven commercialization strategy, failure of products to show sufficient differentiation in targeted therapeutic indications, patent expiry or invalidation, and potential to raise additional funds under poor market conditions." (7/1/2019)
- 3. Cantor Fitzgerald analysts commented, "Our Neutral rating for NVAX stock is based on the uncertainty as to how the company’s technologies will be applied in the successful development of proprietary vaccines and where or how NVAX will access the capital necessary to realize that potential. Positive data for vaccine candidates would be a catalyst for share price appreciation, in our view. Valuation Summary We estimate the aggregate technical value of the programs to be higher than the current market price, but question where/how NVAX could access capital to realize that value." (5/9/2019)
Has Novavax been receiving favorable news coverage?
Press coverage about NVAX stock has trended somewhat positive recently, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novavax earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Novavax.
Who are some of Novavax's key competitors?
Some companies that are related to Novavax include Voyager Therapeutics (VYGR), Mesoblast (MESO), DBV TECHNOLOGIE/S (DBVT), AVITA MED LTD/S (AVMXY), Cellectis (CLLS), Translate Bio (TBIO), Autolus Therapeutics (AUTL), Precision BioSciences (DTIL), Avrobio (AVRO), Solid Biosciences (SLDB), Tcr2 Therapeutics (TCRR), Agenus (AGEN), Harpoon Therapeutics (HARP), Scholar Rock (SRRK) and Replimune Group (REPL).
What other stocks do shareholders of Novavax own?
Who are Novavax's key executives?
Novavax's management team includes the folowing people:
- Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)
- Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)
- Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)
- Dr. Gregory M. Glenn, Pres of R&D (Age 65)
- Ms. Erika S. Trahan, Sr. Mang. of Investor & PR
Who are Novavax's major shareholders?
Novavax's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.86%), Northern Trust Corp (0.99%), Rock Springs Capital Management LP (0.68%), Charles Schwab Investment Management Inc. (0.51%), Bank of New York Mellon Corp (0.43%) and Ontario Teachers Pension Plan Board (0.37%). Company insiders that own Novavax stock include Gregory M Glenn, John Trizzino, Rachel K King and Stanley C Erck. View Institutional Ownership Trends for Novavax.
Which institutional investors are selling Novavax stock?
NVAX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Northern Trust Corp, Rock Springs Capital Management LP, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, Taylor Wealth Management Partners, Swiss National Bank and Wells Fargo & Company MN. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn and John Trizzino. View Insider Buying and Selling for Novavax.
Which institutional investors are buying Novavax stock?
NVAX stock was bought by a variety of institutional investors in the last quarter, including Ontario Teachers Pension Plan Board, A.R.T. Advisors LLC and GSA Capital Partners LLP. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, John Trizzino, Rachel K King and Stanley C Erck. View Insider Buying and Selling for Novavax.
How do I buy shares of Novavax?
Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Novavax's stock price today?
One share of NVAX stock can currently be purchased for approximately $7.57.
How big of a company is Novavax?
Novavax has a market capitalization of $181.09 million and generates $34.29 million in revenue each year. The biopharmaceutical company earns $-184,750,000.00 in net income (profit) each year or ($10.00) on an earnings per share basis. Novavax employs 373 workers across the globe.View Additional Information About Novavax.
What is Novavax's official website?
How can I contact Novavax?
Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]
MarketBeat Community Rating for Novavax (NASDAQ NVAX)
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
